Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10316020" target="_blank" >RIV/00216208:11130/15:10316020 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/15:10316020

Výsledek na webu

<a href="http://dx.doi.org/10.1038/leu.2015.59" target="_blank" >http://dx.doi.org/10.1038/leu.2015.59</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/leu.2015.59" target="_blank" >10.1038/leu.2015.59</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment

Popis výsledku v původním jazyce

The prognosis for children with high-risk relapsed acute lymphoblastic leukemia (ALL) is poor. Here, we assessed the prognostic importance of response during induction and consolidation treatment prior to hematopoietic stem cell transplantation (HSCT) aiming to evaluate the best time to assess minimal residual disease (MRD) for intervention strategies and in future trials in high-risk ALL relapse patients. Included patients (n = 125) were treated uniformly according to the ALL-REZ BFM (Berlin-Frankfurt-Munster) 2002 relapse trial (median follow-up time = 4.8 years). Patients with MRD }= 10(-3) after induction treatment (76/119, 64%) or immediately preceding HSCT (19/71, 27%) had a significantly worse probability of disease-free survival 10 years afterrelapse treatment begin, with 26% (+/- 6%) or 23% (+/- 7%), respectively, compared with 58% (+/- 8%) or 48% (+/- 7%) for patients with MRD < 10(-3). Conventional intensive consolidation treatment reduced MRD to < 10(-3) before HSCT in 63%

Název v anglickém jazyce

Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment

Popis výsledku anglicky

The prognosis for children with high-risk relapsed acute lymphoblastic leukemia (ALL) is poor. Here, we assessed the prognostic importance of response during induction and consolidation treatment prior to hematopoietic stem cell transplantation (HSCT) aiming to evaluate the best time to assess minimal residual disease (MRD) for intervention strategies and in future trials in high-risk ALL relapse patients. Included patients (n = 125) were treated uniformly according to the ALL-REZ BFM (Berlin-Frankfurt-Munster) 2002 relapse trial (median follow-up time = 4.8 years). Patients with MRD }= 10(-3) after induction treatment (76/119, 64%) or immediately preceding HSCT (19/71, 27%) had a significantly worse probability of disease-free survival 10 years afterrelapse treatment begin, with 26% (+/- 6%) or 23% (+/- 7%), respectively, compared with 58% (+/- 8%) or 48% (+/- 7%) for patients with MRD < 10(-3). Conventional intensive consolidation treatment reduced MRD to < 10(-3) before HSCT in 63%

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/GBP302%2F12%2FG101" target="_blank" >GBP302/12/G101: Molekulární mechanismy signalizace receptory leukocytů - jejich role ve zdraví a nemocích.</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia

ISSN

0887-6924

e-ISSN

—

Svazek periodika

29

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

1648-1655

Kód UT WoS článku

000360937200004

EID výsledku v databázi Scopus

2-s2.0-84938969742